Media stories about Insys Therapeutics (NASDAQ:INSY) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insys Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.5135332960694 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

Shares of Insys Therapeutics (NASDAQ:INSY) traded down 1.66% during midday trading on Friday, reaching $8.91. The company’s stock had a trading volume of 565,643 shares. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $18.50. The stock has a 50 day moving average price of $11.86 and a 200-day moving average price of $11.42. The company’s market capitalization is $647.72 million.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. During the same quarter last year, the firm earned $0.13 EPS. Insys Therapeutics’s revenue for the quarter was down 38.4% compared to the same quarter last year. Equities research analysts expect that Insys Therapeutics will post ($0.29) EPS for the current year.

INSY has been the topic of several research reports. Royal Bank Of Canada reissued a “buy” rating and set a $16.00 price target on shares of Insys Therapeutics in a research report on Friday, April 28th. Piper Jaffray Companies lowered Insys Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $20.00 to $10.00 in a research report on Wednesday, May 10th. Jefferies Group LLC reissued a “buy” rating and set a $14.00 price target on shares of Insys Therapeutics in a research report on Friday, June 9th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Finally, BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $13.25.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at

In related news, CEO Saeed Motahari purchased 4,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were acquired at an average price of $11.98 per share, with a total value of $53,910.00. Following the purchase, the chief executive officer now directly owns 4,500 shares in the company, valued at $53,910. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rohit Vishnoi purchased 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was bought at an average cost of $14.14 per share, for a total transaction of $56,560.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $56,560. The disclosure for this purchase can be found here. Insiders have bought a total of 27,400 shares of company stock worth $317,150 in the last three months. 67.90% of the stock is owned by insiders.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with's FREE daily email newsletter.